FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1930000700> ?p ?o ?g. }

• W1930000700 endingPage "2983" @default.
• W1930000700 startingPage "2976" @default.
• W1930000700 abstract "PURPOSE To determine the effects of sargramostim (recombinant human granulocyte-macrophage colony-stimulating factor [rhu GM-CSF]) on the incidence, duration, and complications of myelosuppression after moderate-dose fluorouracil, doxorubicin, cyclophosphamide (FAC) adjuvant chemotherapy in patients with node-positive breast cancer. PATIENTS AND METHODS In this randomized, double-blind, placebo-controlled study, 142 women with stage II and III breast cancer were to receive four 21-day cycles of chemotherapy that consisted of fluorouracil 600 mg/ m2 intravenously (IV), doxorubicin 60 mg/m2 IV, and cyclophosphamide 750 mg/m2 IV on day 1, followed by placebo or GM-CSF 250 micrograms/m2/d daily subcutaneously (SC) on days 3 through 15. All patients received prophylactic ciprofloxacin by mouth when the absolute neutrophil count (ANC) was less than 1,000/microL. RESULTS Eighty-six percent of GM-CSF patients (n = 62) and 96% of placebo patients (n = 69) completed four assessable cycles of treatment on study. Overall, the median duration of severe neutropenia (ANC < 500/microL) was 2.8 days with GM-CSF and 6.8 days with placebo (P < .001); the duration of ANC less than 1,000/microL was 6.0 versus 9.1 days, respectively (P < .001). Hospitalizations for febrile neutropenia were uncommon in either group: GM-CSF, six; placebo, eight. The only other difference in hematologic toxicity was grade 3/4 thrombocytopenia observed with greater frequency in GM-CSF patients than placebo patients in cycles 3 and 4. GM-CSF increased mean the FAC dose-intensity among patients who completed two or more cycles (P < .001). GM-CSF was generally well tolerated and associated with more injection-site reactions, but less mucositis than placebo. There were no deaths on study. CONCLUSION GM-CSF significantly enhanced ANC recovery after FAC chemotherapy; it decreased the incidence and duration of associated neutropenia and moderately increased the dose-intensity of adjuvant chemotherapy. Whether these effects will ultimately translate into improved long-term outcome remains to be determined." @default.
• W1930000700 created "2016-06-24" @default.
• W1930000700 creator A5002951950 @default.
• W1930000700 creator A5003827285 @default.
• W1930000700 creator A5009266124 @default.
• W1930000700 creator A5029394573 @default.
• W1930000700 creator A5041449100 @default.
• W1930000700 creator A5050750455 @default.
• W1930000700 creator A5059388041 @default.
• W1930000700 creator A5060335134 @default.
• W1930000700 creator A5062404192 @default.
• W1930000700 creator A5065915625 @default.
• W1930000700 creator A5066600594 @default.
• W1930000700 creator A5078523405 @default.
• W1930000700 date "1996-11-01" @default.
• W1930000700 modified "2023-10-16" @default.
• W1930000700 title "Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer." @default.
• W1930000700 cites W1529388857 @default.
• W1930000700 cites W1762270685 @default.
• W1930000700 cites W1783403542 @default.
• W1930000700 cites W1828901577 @default.
• W1930000700 cites W1930123912 @default.
• W1930000700 cites W1976476604 @default.
• W1930000700 cites W2018263896 @default.
• W1930000700 cites W2028451463 @default.
• W1930000700 cites W2036067444 @default.
• W1930000700 cites W2072977890 @default.
• W1930000700 cites W2074454485 @default.
• W1930000700 cites W2176794539 @default.
• W1930000700 cites W2214029008 @default.
• W1930000700 cites W2226490553 @default.
• W1930000700 cites W2330558238 @default.
• W1930000700 cites W341557053 @default.
• W1930000700 cites W2313308602 @default.
• W1930000700 doi "https://doi.org/10.1200/jco.1996.14.11.2976" @default.
• W1930000700 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8918495" @default.
• W1930000700 hasPublicationYear "1996" @default.
• W1930000700 type Work @default.
• W1930000700 sameAs 1930000700 @default.
• W1930000700 citedByCount "48" @default.
• W1930000700 countsByYear W19300007002012 @default.
• W1930000700 countsByYear W19300007002013 @default.
• W1930000700 countsByYear W19300007002014 @default.
• W1930000700 countsByYear W19300007002015 @default.
• W1930000700 countsByYear W19300007002017 @default.
• W1930000700 countsByYear W19300007002018 @default.
• W1930000700 countsByYear W19300007002019 @default.
• W1930000700 countsByYear W19300007002021 @default.
• W1930000700 countsByYear W19300007002022 @default.
• W1930000700 crossrefType "journal-article" @default.
• W1930000700 hasAuthorship W1930000700A5002951950 @default.
• W1930000700 hasAuthorship W1930000700A5003827285 @default.
• W1930000700 hasAuthorship W1930000700A5009266124 @default.
• W1930000700 hasAuthorship W1930000700A5029394573 @default.
• W1930000700 hasAuthorship W1930000700A5041449100 @default.
• W1930000700 hasAuthorship W1930000700A5050750455 @default.
• W1930000700 hasAuthorship W1930000700A5059388041 @default.
• W1930000700 hasAuthorship W1930000700A5060335134 @default.
• W1930000700 hasAuthorship W1930000700A5062404192 @default.
• W1930000700 hasAuthorship W1930000700A5065915625 @default.
• W1930000700 hasAuthorship W1930000700A5066600594 @default.
• W1930000700 hasAuthorship W1930000700A5078523405 @default.
• W1930000700 hasConcept C121608353 @default.
• W1930000700 hasConcept C126322002 @default.
• W1930000700 hasConcept C141071460 @default.
• W1930000700 hasConcept C142724271 @default.
• W1930000700 hasConcept C204787440 @default.
• W1930000700 hasConcept C27081682 @default.
• W1930000700 hasConcept C2776694085 @default.
• W1930000700 hasConcept C2776755627 @default.
• W1930000700 hasConcept C2777063308 @default.
• W1930000700 hasConcept C2778850193 @default.
• W1930000700 hasConcept C2780456651 @default.
• W1930000700 hasConcept C2781303535 @default.
• W1930000700 hasConcept C530470458 @default.
• W1930000700 hasConcept C71924100 @default.
• W1930000700 hasConcept C90924648 @default.
• W1930000700 hasConceptScore W1930000700C121608353 @default.
• W1930000700 hasConceptScore W1930000700C126322002 @default.
• W1930000700 hasConceptScore W1930000700C141071460 @default.
• W1930000700 hasConceptScore W1930000700C142724271 @default.
• W1930000700 hasConceptScore W1930000700C204787440 @default.
• W1930000700 hasConceptScore W1930000700C27081682 @default.
• W1930000700 hasConceptScore W1930000700C2776694085 @default.
• W1930000700 hasConceptScore W1930000700C2776755627 @default.
• W1930000700 hasConceptScore W1930000700C2777063308 @default.
• W1930000700 hasConceptScore W1930000700C2778850193 @default.
• W1930000700 hasConceptScore W1930000700C2780456651 @default.
• W1930000700 hasConceptScore W1930000700C2781303535 @default.
• W1930000700 hasConceptScore W1930000700C530470458 @default.
• W1930000700 hasConceptScore W1930000700C71924100 @default.
• W1930000700 hasConceptScore W1930000700C90924648 @default.
• W1930000700 hasIssue "11" @default.
• W1930000700 hasLocation W19300007001 @default.
• W1930000700 hasLocation W19300007002 @default.
• W1930000700 hasOpenAccess W1930000700 @default.
• W1930000700 hasPrimaryLocation W19300007001 @default.
• W1930000700 hasRelatedWork W1973590049 @default.

• next